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Abstract
Background: Trisomic variants of human embryonic stem cells (hESCs) arise spontaneously in culture. Although 
trisomic hESCs share many properties with diploid hESCs, they also exhibit features of cancer stem cells. Since most 
hESC-based therapies will utilize differentiated derivatives, it is imperative to investigate the potential of trisomic hESCs 
to undergo malignant transformation during differentiation prior to their use in the clinical setting.
Methods: Diploid and trisomic hESCs were differentiated into astrocytic progenitors cells (APCs), RNA extracted and 
hybridized to human exon-specific microarrays. Global gene expression profiles of diploid and trisomic APCs were 
compared to that of an astrocytoma cell line and glioblastoma samples, analyzed by others, using the same microarray 
platform.
Results: Bioinformatic analysis of microarray data indicates that differentiated trisomic APCs exhibit global expression 
profiles with similarities to the malignant astrocytoma cell line. An analogous trend is observed in comparison to 
glioblastoma samples indicating that trisomic APCs express markers of astrocytic cancer cells. The analysis also allowed 
identification of transcripts predicted to be differentially expressed in brain tumor stem cells. These data indicate that in 
vitro differentiation of trisomic hESCs along astrocytic pathways give rise to cells exhibiting properties of premalignant 
astrocytic stem/progenitor cells.
Conclusions: Given their occult nature, opportunities to study premalignant stem/progenitor cells in human have 
been few. The ability to propagate and direct the differentiation of aneuploid hESCs provides a powerful in vitro system 
for investigating biological properties of human cells exhibiting features of premalignant stem cells. This in vitro culture 
system can be used to elucidate changes in gene expression occurring enroute to malignant transformation and to 
identify molecular markers of cancer stem/progenitor cells. These markers are invaluable for diagnostic purposes and 
may be novel targets for therapeutic intervention.
Background
Human embryonic stem cells (hESCs) are a source of
pluripotent cells that can be differentiated in vitro into
cells of numerous lineages [1]. The use of hESCs in regen-
erative medicine requires caution since aneuploid vari-
ants of hESCs spontaneously arise in culture. Trisomy for
chromosomes X, 12 and/or 17 is one type of aneuploidy
frequently observed in hESC lines [2]. Trisomic hESC
variants exhibit many properties indistinguishable from
their diploid counterparts; they self-renew, express 'stem'
markers characteristic of diploid hESCs, retain pluripo-
tency, differentiate in vitro and produce teratomas in
mice [3,4]. Trisomic variants appear karyotypically stable
over time in culture and microarray and RT-PCR analyses
indicate that gene expression patterns of trisomic hESCs
are similar to the diploid hESC lines from which they
were derived [3,4]. However, trisomic hESC variants also
display characteristics similar to cancer stem cells; they
exhibit a reduced doubling time and teratomas arising
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from trisomic hESC injection contain a higher percentage
of undifferentiated cells similar to teratocarcinomas
formed following embryonal carcinoma cell injection [3].
Many similarities in gene expression profiles have been
reported for normal and cancer stem cells, suggesting
that changes in expression of relatively few genes may be
sufficient to drive transformation of normal stem cells
into cancer stem cells [5]. Recent evidence indicates that
neural precursors derived from variant hESC lines exhibit
early features of neoplastic transformation, including
increased proliferative capacity and ~20 fold increase in
the frequency of tumor initiating cells when assayed by
injection into NOD-SCID mice [6]. Since cultured hESCs
are genetically unstable and exhibit a propensity to
develop spontaneous trisomy [2,7], it is imperative to
evaluate the potential tumorigenicity of trisomic hESC
variants.
In general, hESC-based cell-replacement strategies will
rely on hESC-derived differentiated cells rather than the
pluripotent stem cells. Thus, the potential of aneuploid
hESC variants to undergo malignant transformation in
the clinical setting is more instructively evaluated by
comparing expression profiles of differentiated deriva-
tives of diploid and trisomic hESCs. The primary objec-
tive of this study was to determine if similarities in gene
expression patterns of diploid and trisomic pluripotent
hESCs are retained following in vitro directed differentia-
tion. To investigate this question, an in vitro culture sys-
tem was developed in which hESCs were differentiated
into homogenous populations of human astrocytic pro-
genitor cells (APCs) suitable for global gene expression
profiling using high-density exon-specific microarrays. If
expression patterns of trisomic hESCs diverge from dip-
loid hESCs following differentiation, then the next objec-
tive was to determine if trisomic derivatives exhibit
expression profiles similar to malignant cell lines and/or
primary tumor samples of the same lineage. Given the
difficulty of isolating sufficient quantities of human pre-
malignant progenitors for sophisticated molecular char-
acterization, the final objective of this study was to
determine if expression patterns of differentiated deriva-
tives of aneuploid hESCs express markers of previously
identified astrocytic cancer stem/progenitor cells. The
results of this analysis indicate that in vitro differentiated
astrocytes derived from a trisomic hESC line exhibit
global gene expression profiles similar to astrocytomas
and astrocytic cancer stem/progenitor cells. The results
demonstrate that the combination of in vitro directed dif-
ferentiation of hESCs, global gene expression profiling
and robust bioinformatic analyses provides a powerful
model system that can be used to identify differentially
expressed biomarkers in stem/progenitor cells in hetero-
geneous tumors.
Methods
HESC and other cell culture
HESC lines H9 (WiCell) and BG01V (American Type
Culture Collection) were grown under feeder-indepen-
dent conditions on matrigel-coated dishes (BD) in
medium containing basal DMEM/F-12 with 1 mM glu-
tamine, 20% knockout serum replacement (KSR; Invitro-
gen), 2 mM non-essential amino acids and 8 ng/ml FGF
(Invitrogen). To obtain non-adherent embryoid bodies,
small pieces of undifferentiated hESC colonies (~100-200
cells) were mechanically dissected and cultured on low
attachment plates in the same media used for maintain-
ing pluripotent hESCs, except KSR was removed and
replaced with 10% Fetal Bovine Serum (FBS; Hyclone).
Neurospheres were derived from 4-5 day old embryoid
bodies and grown in suspension for two weeks in
medium containing DMEM/F-12 with 2 mM L-glu-
tamine, 10 μl/ml BIT9500 (StemCell Technologies) sup-
plemented with 10 ng/ml FGF, 10 ng/ml EGF (Millipore).
To obtain astrocytic progenitor cells, neurospheres were
allowed to adhere on matrigel-coated plates and differen-
tiated in the presence of CCF-STTG1 conditioned media
supplemented with 10 ng/ml EGF. CCF-STTG1 cells, a
grade IV human astrocytoma cell line, were obtained
from American Type Culture Collection and cultured in
growth medium containing DMEM/F-12 with 2 mM L-
glutamine, 1 mM sodium pyruvate, 4.5 g/l glucose, 1.5 g/l
sodium bicarbonate supplemented with 10% FBS, under
5% CO2 at 37°C.
Immunocytochemical characterization
Human ESCs grown on matrigel-coated LabTek chamber
slides were rinsed with 1× PBS and fixed in 4% paraform-
aldehyde for 30 minutes at room temperature. Immuno-
fluorescence staining was performed according to
instructions provided in the Stem Cell Characterization
Sample Kit (Millipore). The following primary antibodies
were used at 1:200 dilutions: anti-TRA-1-60 (Millipore)
and OCT-4 (Cell Signaling). Secondary antibodies, rhod-
amine-conjugated anti-mouse IgG or IgM or Cy2-conju-
gated anti-mouse IgM or IgG (Jackson Immunoresearch
Laboratories Inc.) were used to detect primary antibody
at 1:500 dilutions. H9 and BG01V APCs were cultured in
matrigel-coated 24-well plates, the cells rinsed with 1×
PBS and fixed in 4% paraformaldehyde for 30 minutes at
room temperature. An astrocyte-specific primary anti-
body directed against glial fibrillary acidic protein (α-
GFAP, Chemicon) was used at 1:200 dilution. Secondary
antibody, rhodamine-conjugated anti-mouse IgG (Jack-
son Immunoresearch laboratories Inc.) was used to
detect GFAP positive cells. Images were visualized with
an Inverted IX81 (Olympus) fluorescence microscope
and captured on a Retiga 2000R cooled CCD color cam-
era (QImaging).Gopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
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Exon microarrays and data analysis
Affymetrix Human Exon 1.0ST microarrays were
selected as the platform for global gene expression profil-
ing because they contain 1.4 million probesets, including
four oligonucleotides for each known or predicted exon
in the human genome, and are expected to be more com-
prehensive than Affymetrix U133 Plus 2 microarrays,
where most probesets are clustered in and around 3'
regions of genes. Additional information can be obtained
from the Affymetrix website http://www.affymetrix.com.
RNA was isolated from three independent cultures of
each cell type using the Trizol method (Invitrogen) and
RNA quality determined by Nanodrop technique (Nano-
Drop T echnologies). One μg of total RNA was used for
preparation of individual samples. Microarray hybridiza-
tion, scanning and data acquisition were performed at the
City of Hope Microarray Core Facility. All microarray
data were analyzed using Partek Genomic Suite software.
Signal estimates obtained from CEL files were quantile-
sketch normalized using the RMA algorithm for core
probeset intensities. They were adjusted for "Detection
Above Background", using surrogate GC mismatch inten-
sities. Imported log2-transformed exon intensities were
subjected to one-way ANOVA (analysis of variance) for
comparison between the three biological replicates of
each cell population, except glioblastoma samples where
the 23 individual patient samples were treated as one cell
population. Unsupervised hierarchical cluster analysis,
heat maps and individual gene dot plots were generated
using Partek Genomic Suite software. High-end (over) or
low-end (under) expression is indicated by red and blue,
respectively, in the heat maps. Expression level of each
gene in each cell population was measured relative to the
median expression level across the three replicates and
variations between cell populations graphically depicted
using individual gene dot plots, where the horizontal line
within the colored bar represents the median expression
level within each population and the vertical length of the
bar represents SEM. Supervised hierarchical analyses, fil-
tered at p value < 0.02 as described in detail in Results,
was used to generate gene lists. Please see the Partek web-
site http://www.partek.com/ for a more detailed descrip-
tion of statistical analysis of microarray data using the
Partek Genomic Suite applications. Exon array data of 23
glioblastoma samples were extracted from GEO database:
GSE9385 [8]. Exon microarray data of H9 APC, BG01V
APC and CCF-STTG1 cells have been deposited at
ArrayExpress http://www.ebi.ac.uk/arrayexpress: acces-
sion number is E-MEXP-2633.
Semi-quantitative RT-PCR, DNA sequencing and 
quantitative RT-PCR analyses
H9 and BG01V hESCs cultured on matrigel were har-
vested after five to six days in culture. APCs were har-
vested on the fifth passage after neurospheres were
differentiated into astrocytic progenitors on matrigel-
coated plates. Total RNA was extracted using TRIzol
according to the manufacturer's instructions (Invitrogen).
Gene-specific PCR primers located within exons or span-
ning exon junctions were designed based on human gene
sequences obtained from Ensembl http://
www.ensembl.org/. Sequences of PCR primers are shown
in Additional file 1, Table S1. Synthesis of cDNA was per-
formed using 2 μg of total RNA, SuperScript II reverse
transcriptase (Invitrogen) and random primers. Semi-
quantitative RT-PCR reactions used 1 μl of cDNA tem-
plate and exon-specific primers. PCR products were
resolved by electrophoresis on 1.5% agarose gels and
visualized by ethidium bromide staining. Data were
recorded using QuantityOne software (BioRad). PCR
product of interest was excised, purified and cloned into
StrataClone vector using the PCR Cloning Kit (Strata-
gene) and the DNA insert sequenced using T3 or T7
primers. Quantitative PCR reactions (25 μl) were per-
formed in an iCycler (BioRad) using 1 μl cDNA template,
exon primers for the gene in question and SYBR green
PCR mix (Applied Biosystems). Relative quantification
was determined using the ΔΔCT method [9] according to
the manufacturer's protocol (BioRad). Quantitative RT-
PCR analysis using Human Cancer Pathway Finder PCR
Arrays (SuperArray, Biosciences Corporation) containing
proprietary RT-PCR primers for a number of cancer-
associated genes was carried out according to the manu-
facturer's instructions using 1 μl cDNA template.
Results
Derivation of astrocytic progenitor cells from hESCs
Diploid H9 and trisomic BG01V hESCs were grown on
mouse embryonic fibroblasts, transferred to matrigel and
cultured under feeder-independent conditions for subse-
quent immunofluorescent and molecular characteriza-
tion (Figure 1A). Both H9 and BG01V hESCs express
OCT-4 and TRA-1-60 (Figure 1A) and other markers
characteristic of pluripotent hESCs, including TRA-1-81
and SSEA-4 (not shown). Examples of H9 diploid karyo-
type (46; XX) and aneuploid BG01V karyotype (49; XXY,
+12, +17) are shown in Figure 1A. H9 and BG01V hESCs
were cultured under non-adherent conditions that pro-
mote differentiation into embryoid bodies and subse-
quent neurosphere formation as described in Methods.
Floating hESC-derived neurospheres were allowed to set-
tle on matrigel-coated dishes and differentiated into
adherent astrocytic progenitor cells (APCs). Astrocytic
nature of APCs was confirmed by staining for GFAP (Fig-
ure 1A) and additional molecular analyses described
below. Semi-quantitative RT-PCR analysis demonstrates
over expression of stem cell transcripts, NOGGIN and
LIN28, in pluripotent H9 and BG01V hESCs relative toGopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
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astrocytic-like cells (H9 APCs, BG01V APCs and CCF-
STTG1 astrocytoma cells), while over expression of
GFAP RNA is observed in all astrocytic-like cells relative
to both hESC lines (Figure 1B). H9 and BG01V hESCs
both express a FGFR1 mRNA including exon 3 (upper
band), while all three astrocytic-like cells express a
Figure 1 Diploid and trisomic astrocytic progenitors derived by directed in vitro differentiation of hESCs exhibit transcript and alternative 
splicing patterns characteristic of astrocytic cells. A. Diploid H9 and trisomic BG01V hESCs colonies (unstained, left panels), express stem cell mark-
ers OCT-4 (red) and TRA-1-60 (green). Karyotypes of diploid H9 (46; XX) and trisomic BG01V (49; XXY, +12, +17) hESCs. Diploid and trisomic APCs ex-
press astrocytic marker, GFAP (red). B. Semiquantitative RT-PCR analysis demonstrating that stem cell transcripts Noggin (top panel) and Lin28 (second 
panel) are over expressed in both diploid H9 and trisomic BG01V hESC lines relative to all astrocytic-like cells including H9 APCs, BG01V APCs and CCF-
STTG1 astrocytoma cells. GFAP transcripts are up regulated in astrocytic cells relative to hESCs (middle panel). Alternative splicing pattern of FGFR1 in 
diploid H9 hESCs is preserved in trisomic BG01V hESCs relative to all astrocytic cells. 18S RNA was used as control in all RT-PCR experiments (bottom 
panel). MW marker is included in the far left lane in each gel. C. DNA sequence analysis demonstrating that the FGFR1 transcript expressed in diploid 
H9 and trisomic BG01V hESCs includes exon 3, while astrocytic cells express a FGFR1 splice variant in which exon 3 has been excluded (from FGFR1 RT-
PCR analysis in Figure 1B).
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FGFR1 alternatively spliced variant in which exon 3 has
been excluded from the mature transcript (lower band)
(Figure 1B). Inclusion of FGFR1 exon 3 in pluripotent
hESCs and exon 3 exclusion from astrocytic-like cells was
confirmed by sequencing of the PCR product extracted
from the gel (Figure 1C).
Gene expression profile of trisomic APCs is similar to CCF-
STTG1 astrocytoma cells
RNA samples extracted from three independent cultures
of each of the three astrocytic-like cell populations (dip-
loid H9 APCs, trisomic BG01V APCs and CCF-STTG1
astrocytoma cells) were used for microarray analysis. The
nine RNA samples were subjected to linear amplification,
labeling and hybridized to Affymetrix Human Exon
1.0ST microarrays. Statistical analysis of variance
(ANOVA) of microarray data was performed using
Partek Genomics Suite software applications as described
in the Methods section. Excellent overall agreement
among the three biological replicates of each cell type is
readily apparent in the heat map generated by hierarchi-
cal clustering (Figure 2A), which displays all statistically
significant (p value < 0.001) differences in relative expres-
sion levels between diploid H9 APCs (samples C), tri-
s o m i c  B G 0 1 V  A P C s  ( s a m p l e s  G )  a n d  C C F - S T T G 1
astrocytoma cells (samples D). This unsupervised hierar-
chical clustering indicates that the global gene expression
profile of trisomic BG01V APCs shares many similarities
with the malignant astrocytoma cells. Examples of log2-
transformed, fold-changes in geometric mean expression
levels of four transcripts are shown in Figure 2; two
exhibiting significant over expression in trisomic BG01V
APCs and CCF-STTG1 cells relative to H9 APCs,
CPXM1  (Figure 2B) and PIK3R1  (Figure 2C), and two
exhibiting significant under expression in trisomic
BG01V APCs and CCF-STTG1 cells relative to H9 APCs,
TRPA1 (Figure 2D) and GABRA2 (Figure 2E).
Numerous transcripts exhibit differences in relative
expression levels (either over or under expression) in each
of the three individual pair wise comparisons (GvC: 2929
differentially expressed transcripts, DvC: 4019 and GvD:
5193). Because the BG01V trisomic hESC line was not
derived from the diploid H9 hESC line, and neither hESC
line is related to the CCF-STTG1 astrocytoma cell line,
many of these differences in expression levels undoubt-
edly arise from inherent genetic differences between the
three distinct cell lines. It is for this reason that one can-
not rely solely on the individual pair wise comparisons to
identify the most statistically significant differences in
gene expression. Rather, we focused on those gene tran-
scripts exhibiting consistent sign changes in expression
levels in both the BG01V APCs (G) and CCF-STTG1
astrocytoma cell line (D) relative to the H9 APCs (C) (i.e.
both over expressed in BG01V APCs and CCF-STTG1
cells relative to H9 APCs or both under expressed in
BG01V APCs and CCF-STTG1 cells relative to H9
APCs). Those transcripts exhibiting consistent sign
changes in relative expression levels are identified by per-
forming an analysis of variance (ANOVA) of the super-
vised hierarchical clustering; i.e. an ANOVA of the
intersection of the two individual data sets (or the group
comparison).
The power of the group comparison for refining the list
of statistically significant differentially expressed tran-
scripts is illustrated in Figure 3. The number of differen-
tially expressed transcripts detected by ANOVA of the
individual pair wise comparisons is 2929 for GvC and
4019 for DvC comparisons, and the total number of
unique transcripts exhibiting differential expression in
either the GvC or the DvC pair wise comparison - or the
G+DvC data set - is 4115 (Figure 3, upper panel). How-
ever, the majority of these 4115 transcripts are not consis-
tently over expressed (or consistently under expressed) in
both BG01V APCs and CCF-STTG1 cells relative to H9
APCs. As indicated in Figure 3 (lower panel), transcripts
exhibiting consistent sign changes in expression levels are
identified by the group comparison (the intersect of the
two data sets or the GDvC comparison). Once subjected
to these more stringent criteria, the number of differen-
tially expressed transcripts is reduced to only 1416. Thus,
the group comparison is used to reduce the number of
false positives that are scored as statistically significant in
the individual pair wise comparisons (and which may
arise solely from cell line specific differences in gene
expression). These 'false positive' transcripts are elimi-
nated because they do not meet the threshold of statisti-
cal significance as determined by ANOVA of the group
comparison.
The complete list of 1416 transcripts that meet this
higher threshold of significance is shown in Additional
file 2, Table S2 (the GDvC comparison), where gene tran-
scripts are listed in descending order on the basis of the
combined average fold-change in expression levels in
BG01V APC (samples G) and CCF-STTG1 astrocytoma
c e l l s  ( s a m p l e s  D )  r e l a t i v e  t o  H 9  A P C s  ( s a m p l e s  C ) .
Although differences in mean expression levels of several
transcripts are observed between BG01V APCs and
CCF-STTG1 astrocytoma cells, visual inspection of the
Additional file 2, Table S2 data set indicates that the
ANOVA of the group comparison successfully eliminated
most false positives. More than 96% of the 1,416 identi-
fied transcripts exhibit consistent sign changes; ~33% are
over expressed and ~63% are under expressed in both
BG01V APCs and CCF-STTG1 astrocytoma cells relative
t o dipl oid H9 APC s.  F ew er  t han 4% o f  t he  t ra nscrip ts
show inconsistent sign changes (i.e. under expressed in
BG01V APCs and over expressed in CCF-STTG1 cells
relative to H9 APCs or over expressed in BG01V APCsGopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
http://www.biomedcentral.com/1755-8794/3/12
Page 6 of 18
and under expressed in CCF-STTG1 cells relative to H9
APCs). Most of the inconsistent transcripts exhibit only
minor changes in relative expression levels (~10% to 20%
increase or decrease) and relatively insignificant p values.
In contrast, approximately 130 of the consistently over
expressed transcripts show at least a two-fold increase in
mean expression level in each individual pair wise com-
parison, BG01V APCs (samples G) vs. H9 APCs (samples
C) and CCF-STTG1 (samples D) vs. H9 APCs (samples
C), and far greater significance with p values less than ~2
× 10-9.
Many of the consistently and abundantly over
expressed transcripts in trisomic BG01V APCs and CCF-
STTG1 astrocytoma cells encode proteins previously
implicated in cancer in general or associated with astro-
cytomas specifically, including HSPA1A,  HOXD10,
GPNMB, GUCY1B3, GUCY1A3, HDAC9, APOE, CTSH,
THRB, RAB38 and PIK3R1 [10-21]. Transcripts exhibit-
ing significant under expression in trisomic BG01V APCs
and CCF-STTG1 astrocytoma cells relative to diploid H9
APCs include several markers of normal differentiated
astrocytes, including TRPA1, GABRA2, BDNF, BDKRB1
and BDKRB2 [22-24]. This result suggests that directed
differentiation of trisomic hESCs along an astrocytic lin-
eage produces astrocytic progenitor cells with an inter-
mediate phenotype; although BG01V APCs continue to
express many biomarkers of normal, differentiated astro-
Figure 2 Global gene expression profile of trisomic BG01V APCs is similar to CCF-STTG1 astrocytoma cells. A. Heat map of unsupervised hier-
archical cluster analysis of exon microarray hybridization data derived from the three diploid H9 APC samples (C), the three trisomic BG01V APC sam-
ples (G) and the three CCF-STTG1 astrocytoma cell samples (D). Relative over expression is indicated by red and under expression by blue in the heat 
map. Microarray data was filtered using a p value < 0.001. Individual gene dot plots showing changes in mean expression levels of transcripts CPXM1 
(panel B), PIK3R1 (panel C), TRPA1 (panel D) and GABRA2 (panel E). Each panel shows the individual hybridization data for all nine samples, including 
the three biological replicates of diploid H9 APCs (red), the three independent replicates of trisomic BG01V APCs (green) and the three CCF-STTG1 
astrocytoma cell samples (blue).
DC G A CPXM1 PIK3R1
TRPA1
B C
D E
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cytes (similar to diploid H9 APCs), they also express
numerous markers that are characteristic of the malig-
nant astrocytoma cell line (CCF-STTG1).
RT-PCR validation of differentially expressed transcripts in 
trisomic and diploid hESC-derived APCs
Both semi-quantitative and quantitative RT-PCR analyses
were used to validate changes in expression levels of sev-
eral transcripts detected by microarray analysis. Semi-
quantitative RT-PCR analyses of nine transcripts that are
over or under expressed in trisomic BG01V APCs and
CCF-STTG1 astrocytoma cells relative to H9 APCs are
shown in Figure 4A. Differential expression of transcripts
identified by exon array analyses were also validated by
qRT-PCR analyses using forward primers flanking unique
exon junctions in conjunction with exon-specific reverse
primers (Figure 4B). A success rate of greater than 93%
was obtained for qRT-PCR validation of genes detected
when microarray data was filtered at p value < 0.02. Addi-
tional differentially expressed transcripts that were vali-
dated by qRT-PCR analyses are listed in Additional file 1,
Table S1. Human Cancer Pathway Finder PCR Arrays
were used as a third method to evaluate relative changes
in gene expression levels in diploid H9 and trisomic
BG01V APCs. The Cancer Pathway Finder Array analysis
identified numerous cancer-associated genes exhibiting
substantial over expression in trisomic BG01V APCs rel-
ative to diploid H9 APCs, including CDC25A,  IGF1,
MMP9, FGFR2, BRCA1, CASP8 and TERT1 (Additional
file 3, Figure S1).
Trisomic APCs express markers of astrocytic cancer cells
Similarities in global gene expression profiles of BG01V
APCs and CCF-STTG1 astrocytoma cells might arise
from in vitro culture conditions used to direct astrocytic
differentiation and/or from some characteristic of the
CCF-STTG1 astrocytoma cell line used for individual
pair wise and group comparisons. To exclude these possi-
bilities, H9 and BG01V APCs expression profiles were
also compared to twenty-three human glioblastoma
patient samples analyzed using the same microarray plat-
form [8]. Because we are interested in identifying expres-
sion changes in astrocytomas, all microarray data of
histopathologically confirmed oligodendroglioma sam-
ples were excluded from this analysis. The heat map of
hierarchical clustering of all transcripts exhibiting signifi-
cant differences in relative expression levels in glioblas-
t o m a  s a m p l e s ,  t r i s o m i c  B G 0 1 V  A P C s  a n d  d i p l o i d  H 9
APCs, filtered at a p value of < 0.001, is shown in Figure 5.
This unsupervised hierarchical clustering demonstrates
an obvious and striking similarity in overall gene expres-
sion profiles of the glioblastoma patient samples (samples
N) and trisomic BG01V APCs (samples G) that is mark-
edly distinct from the expression profile of diploid H9
APCs (samples C). This notable similarity indicates that,
following differentiation along astrocytic pathways, tri-
somic BG01V APCs display a global gene expression pro-
file that is more similar to human astrocytomas than to
normal, diploid APCs. Examples of relative changes in
individual expression levels of four genes are shown in
Figure 5. Transcripts encoding the transmembrane glyco-
protein, GPNMB, (Figure 5B) and histone deacetylase 9,
HDAC9 (Figure 5C), are both over expressed in trisomic
BG01V APCs and glioblastoma samples relative to dip-
loid H9 APCs. In contrast, the O-6-methylguanine-DNA
methyltransferase gene, MGMT  (Figure 5D), and the
tumor necrosis factor receptor family member,
TNFRSF11b (Figure 5E), are both under expressed in ane-
uploid astrocytic-like cells relative to diploid H9 APCs.
To identify those transcripts exhibiting consistent sign
changes in expression levels in both BG01V APCs (G)
and glioblastoma patient samples (N) relative to H9 APCs
(C), the intersection of the two data sets - GvC (2929 dif-
ferentially expressed transcripts) and NvC (6611 differen-
tially expressed transcripts) - was obtained by performing
an ANOVA of the supervised hierarchical clustering (i.e.
the group comparison). The intersect data set, GNvC,
identifies 1,038 transcripts exhibiting statistically signifi-
cant differential expression in both BG01V APCs and the
twenty-three glioblastoma samples relative to H9 APCs
(Additional file 4, Table S3). As illustrated in the Venn
diagram in Figure 6, the intersection of Additional file 2,
Figure 3 Intersection of microarray data identifies common 
markers of astrocytic cancer cells. Venn diagram depicting the over-
lap, identified by the supervised hierarchical analysis, between the two 
pair wise comparisons, GvC and DvC, that was used to identify the 
1038 transcripts exhibiting consistent sign changes in expression pat-
terns in trisomic BG01V APCs (samples G) and the CCF-STTG1 astrocy-
toma cell line (samples D) relative to diploid H9 APCs (samples C), 
which constitutes the GDvC gene list shown in Additional file 2, Table 
S2.
GDvC DvC
1416
GvC
1512 2602
G+DvC GvC
2929 4019
+ = DvC
4115
Addition of indivdiual pairwise comparisons
Intersect of indivdiual pairwise comparisons
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Table S2 (the GDvC group comparison) and Additional
file 4, Table S3 (the GNvC group comparison), was used
to further refine the gene list. The intersection of the two
group comparisons identified 499 transcripts exhibiting
consistent changes in expression levels in all classes of
aberrant astrocytes, including trisomic BG01V APCs (G),
glioblastoma samples (N) and CCF-STTG1 astrocytoma
cells (D) relative to normal, diploid H9 APCs (C). The
complete list of 499 transcripts is shown in Additional file
5, Table S4 (the GNDvC group comparison). A subset of
the over expressed transcripts identified by this analysis,
which exhibit at least three-fold over expression, is shown
in Table 1 (GND > C). The finding of statistically signifi-
cant and consistent over expression of these transcripts
in all classes of aneuploid astrocytes including trisomic
BG01V APC samples (G) glioblastoma patient samples
(N) and cultured astrocytoma cell samples (D) suggests
they encode markers characteristic of astrocytic cancer
cells. This list includes, among others, CSRP1, HSPA1A,
TUBB2B, GPNMB, PSMD5, PTPRD, APOE, MAGEH1,
TYW3,  SESN3,  CTSH,  CRYZ,  PIK3R1,  TAF9B,
GUCY1A3,  GPRC5B,  CPXM1,  HDAC9,  GUCY1B3,
SIPA1L2, HNMT and THRB many of which have been
Figure 4 Similarities in expression changes in trisomic APCs and astrocytoma cells were validated by RT-PCR analyses. A. Semi-quantitative 
RT-PCR analysis shows relative under expression of COL4A6, GABRA2, MGMT and TRPA1 (left panels), and over expression of HDAC9, CPXM1, DNMT3A, 
GUCY1A3 and STAT3 (right panels) transcripts in trisomic BG01V APCs and CCF-STTG1 astrocytoma cells with respect to diploid H9 APCs. 18S RNA was 
used as a control. B. Quantitative RT-PCR validation of relative changes in expression levels of the transcripts shown in panel A in diploid H9 APCs (blue 
bars), trisomic BG01V APCs (yellow bars) and astrocytoma cells (red bars).
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previously associated with cancer and some specifically
with astrocytomas [10,11,13-20].
Trisomic APCs express markers of astrocytic cancer stem/
progenitor cells
As indicated in Figure 6, 539 gene transcripts are differ-
entially expressed in glioblastoma patient samples and
BG01V APC samples relative to H9 APC samples (GNvC
group) that are not  also differentially expressed in the
GDvC group comparison. Glioblastomas contain a het-
erogeneous mix of cells including rapidly proliferating
malignant cells as well as slowly cycling cancer stem/pro-
genitor cells. These putative brain tumor stem cells may
c o m p r i s e  o n l y  a  s m a l l  p e r c e n t a g e  o f  t h e  t u m o r  m a s s .
Markers of brain tumor stem cells are reportedly down
regulated when glioblastoma cell lines are grown as
adherent cultures [25,26]. We reasoned that markers of
slowly-cycling, premalignant astrocytic stem/progenitor
cells would be over expressed in the 23 glioblastoma sam-
ples (N) and trisomic BG01V APCs (G), but under
expressed in the adherent CCF-STTG1 astrocytoma cell
line (D) and H9-derived APCs (C). As illustrated in Fig-
ure 7, transcripts meeting these criteria are identified by
performing an ANOVA of the intersection of the four
individual pair wise comparisons - GvC, NvC, GvD and
NvD - or the GNvCD group comparison. This group
analysis identified 311 gene transcripts exhibiting signifi-
cant differential expression when filtered using a p value
of < 0.02 (Additional file 6, Table S5), of which approxi-
mately 75 transcripts were over expressed in both tri-
somic BG01V APCs (G) and glioblastoma samples (N)
relative to diploid H9 APCs (C) and CCF-STTG1 astrocy-
Figure 5 Gene expression profile of trisomic BG01V APCs is similar to glioblastomas. A. Heat map of unsupervised hierarchical cluster analysis 
of microarray hybridization data derived from the twenty-three glioblastoma patient samples (N), the three trisomic BG01V APC samples (G) and the 
three diploid H9 APC samples (C). Relative over expression is indicated by red and under expression by blue in the heat map. Data filtered using a p 
value of < 0.001. Individual gene dot plots displaying changes in mean expression levels of four transcripts: GPNMB (panel B), HDAC9 (panel C), MGMT 
(panel D) and TNFRSF11b (panel E). Each panel shows the individual hybridization data for all samples from each of the three groups, including the 
twenty-three glioblastoma samples (green), the three biological replicates of trisomic BG01V APCs (blue) and the three independent replicates of dip-
loid H9 APCs (red).
N GC
B C
A
HDAC9
MGMT
GPNMB
DE
TNFRSF11bGopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
http://www.biomedcentral.com/1755-8794/3/12
Page 10 of 18
t om a  c e l ls  (D) .  A su bset  of  t hese  ove r  e x pr es sed t ra n-
scripts, which are predicted to encode biomarkers of
premalignant astrocytic stem/progenitor cells, is shown
in Table 2 (GN > CD).
Individual gene dot plots displaying relative expression
levels of several of the GN > CD transcripts are shown in
Figure 8. Included is at least one transcript, PROM1 (Fig-
ure 8A), encoding the CD133 cell surface marker, which
has been classified as a biomarker of brain tumor stem
cells defined as those cells responsible for giving rise to
rapidly proliferating, serial transplantable glioblastomas
in immunocompromised mice [25,26]. PROM1, however,
is neither the most statistically significant (p value of 4.08
× 10-5) nor the most abundantly over expressed (7.34
fold) transcript in Additional file 6, Table S5. Additional
biomarkers indentified by the analysis exhibiting greater
increases in relative expression levels (> 30 fold) and/or
lower p values (< 7.90 × 10-11), include CHI3L1 (Figure
8B), RGS5 (Figure 8C) and IGFBP2 (Figure 8D), which
have been shown to be over expressed in malignant astro-
cytomas - particularly recurrent glioblastomas that often
contain a higher percentage of brain tumor stem cells
[27,28] - suggesting that these may be more reliable bio-
markers of brain tumor stem cells than CD133 (PROM1).
The finding of significant over expression of biomarkers
of brain tumor stem cells in the GN > CD data set sug-
gests that this system can be used to refine the definition
of a human astrocytic cancer stem/progenitor cell by
identifying additional biomarkers that have not previ-
ously been associated with brain tumor stem cells. Indi-
vidual dot plots of other over expressed transcripts
identified in the GD > CD data set, including PPP2R2B
(Figure 8E), LPHN2 (Figure 8F), KCNMB4 (Figure 8G),
ASTN1 (Figure 8H) and GPC4 (Figure 8I) are shown.
Discussion
In this study, an in vitro culture system was developed to
differentiate diploid and trisomic hESCs into astrocytic
progenitor cells (APCs), which were used to determine if
gene expression profiles of trisomic APCs remain similar
to, or deviate from, diploid APCs following astrocytic dif-
ferentiation. The data indicate that expression profiles of
trisomic BG01V APCs diverge considerably from diploid
H 9  A P C s .  A n a l y s i s  o f  h i g h - d e n s i t y  m i c r o a r r a y  d a t a
revealed numerous, highly significant differences in tran-
script expression levels in trisomic BG01V APCs relative
to diploid H9 APCs. Similar differences were observed
when the human astrocytoma cell line, CCF-STTG1, was
compared to diploid H9 APCs. Several expression level
changes, initially detected by microarray analysis, were
subsequently confirmed by qRT-PCR validation. A
remarkably similar trend was observed when trisomic
B G 0 1 V  A P C s  w e r e  c o m p a r e d  t o  h u m a n  g l i o b l a s t o m a
patient samples. Taken together, the data suggest that fol-
lowing differentiation along an astrocytic pathway tri-
somic BG01V APCs exhibit a global gene expression
profile that is more similar to astrocytic cancer cells that
to normal diploid hESC-derived APCs.
Although trisomic BG01V APCs continue to express
markers of differentiated astrocytes, they are clearly dis-
tinct from diploid H9 APCs. Despite the high PROM1
expression in BG01V APCs when cultured under adher-
ent conditions, there is insufficient evidence to classify
trisomic BG01V APCs as brain tumor-initiating cells
[25,26]. Although trisomic BG01V APCs were derived
from multipotent neurospheres that give rise to oligoden-
drocytes or neurons under different culture conditions
(Gopalakrishna-Pillai and Iverson, unpublished), it is also
incorrect to consider BG01V APCs equivalent to trans-
formed neural stem cells. Unlike the CCF-STTG1 astro-
cytoma cells, BG01V APCs do not readily dedifferentiate
into non-adherent neurospheres (not shown). Thus, it
may be more appropriate to consider trisomic BG01V
APCs as one type of premalignant astrocytic stem/pro-
g e nit or c e ll . BG 01V APC s  e xhibi t a n incr eased r a t e  of
proliferation relative to diploid H9 APCs and display gene
expression patterns more similar to the astrocytoma cell
line and glioblastoma patient samples. Trisomic BG01V
APCs may be predisposed to becoming astrocytic cancer
cells, but have not yet acquired the full spectrum of muta-
tions required for malignant transformation.
Because the BG01V trisomic hESC line studied here
was not derived from the diploid H9 hESC line used for
Figure 6 Intersection of microarray data identifies markers of as-
trocytic cancer cells. Venn diagram depicting the overlap between 
the two datasets, GDvC (Additional file 2, Table S2) and GNvC (Addi-
tional file 4, Table S3) that was used to identify the 499 transcripts ex-
hibiting similar changes in expression patterns in all aneuploid 
astrocytic cell populations including trisomic BG01V APCs (samples G), 
glioblastoma patients (samples N) and CCF-STTG1 astrocytoma cells 
(samples D) relative to normal, diploid H9-derived APCs (samples C), 
which constitutes the GNDvC gene list shown in Additional file 5, Table 
S4.
GDvC GNvC
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GNDvC
Table S4
918 539
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Table 1: Markers over expressed in astrocytic cancer cells (GND > C).
Gene
symbol
Accession
number
Fold change
CSRP1 NM_004078 57.34
HSPA1A NM_005345 28.56
TUBB2B NM_178012 19.70
GPNMB NM_001005340 17.55
PSMD5 NM_005047 17.52
PTPRD NM_002839 12.00
APOE NM_000041 11.27
MAGEH1 NM_014061 10.26
TYW3 NM_138467 9.56
SESN3 NM_144665 8.03
CTSH NM_004390 7.88
CRYZ NM_001889 7.81
PIK3R1 NM_181523 6.50
TAF9B NM_015975 6.17
ETV1 NM_004956 6.08
GUCY1A3 NM_000856 5.87
GPRC5B NM_016235 5.84
CPXM1 NM_019609 5.38
HDAC9 NM_178423 5.15
GUCY1B3 NM_000857 4.76
SIPA1L2 NM_020808 4.47
HNMT NM_006895 4.29
SHMT1 NM_004169 3.46
THRB NM_001128177 3.13
A subset of gene transcripts derived from Additional file 5, Table S4 exhibiting at least three-fold over expression in trisomic BG01V APCs (G), 
glioblastoma samples (N) and CCF-STTG1 astrocytoma cells (D) relative to diploid H9 APCs (C), which was obtained by filtering data using a p 
value < 0.02. Fold change was derived from the GNvC group comparison in Additional file 5, Table S4.Gopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
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comparison, the results of this analysis cannot be used to
identify those changes in gene expression that are pre-
dicted to be initiators of premalignant transformation or
tumorigenesis (i.e. changes in gene expression that cause
transformation). However, group analyses of the data sets
can be used to identify differentially expressed transcripts
in normal differentiated astrocytes/astrocytic progenitors
relative to astrocytic cancer cells. For example, highly sig-
nificant decreases in expression levels of several tran-
scripts encoding known markers of normal astrocytes
including TRPA1, BDNF and MGMT were detected by
the analyses. Down regulation of MGMT transcript lev-
els, via hypermethylation of the MGMT  promoter, is
associated with malignant progression of astrocytomas
and is being used in the clinic to identify patients that
may benefit the most from treatment with temozolomide
[29,30]. Thus, transcripts exhibiting highly significant
over expression in all classes of abnormal astrocytes,
including trisomic BG01V APCs, CCF-STTG1 astrocy-
toma cells and glioblastoma patient samples with respect
to diploid H9 APCs (Table 1, GND > C) may be diagnos-
tic markers of transformation and/or potential therapeu-
tic targets (i.e. changes in gene expression that are
consequences of transformation). This list includes cell
surface expressed markers such as GPRC5, signaling mol-
ecules such PIK3R1 and the histone deacetylase, HDAC9,
for which small molecule inhibitors are currently under
investigation in glioblastoma clinical trials [13,31].
Neural stem cells with astrocytic character arising in
the sub ventricular zone are thought to be one source of
origin of gliomas [32,33]. Donor-derived neural stem cells
were recently demonstrated to give rise to tumors of gli-
oneuronal origin in an Ataxia Telangiectasia patient [34].
Slowly cycling cancer stem cells, which are refractory to
conventional radiation and chemotherapy, are thought to
be a source of both the original tumor as well as recurrent
tumors. These astrocytic cancer stem cells create an
obstacle for effective treatment of malignant gliomas, yet
identification of molecular markers characteristic of
brain tumor stem cells is a major challenge complicated
by their low numbers, elusive nature, heterogeneity of
brain tumors and the difficulty of obtaining abundant
quantities of normal human astrocytes that can serve as
controls for global expression analyses [32]. As a result,
gene expression profiles of rare subpopulations of brain
tumor stem cells cannot be readily identified by microar-
ray analyses of brain tumor samples. The system used in
this study describes methods for both obtaining sufficient
quantities of suitable control cells via directed differentia-
tion of hESCs and using gene expression profiles of these
cells to refine the list of putative biomarkers of the astro-
cytic cancer stem cells through rigorous bioinformatic
analyses of the microarray data.
Given their astrocytic, premalignant and stem-like
properties, the class of transcripts predicted to be bio-
markers of premalignant astrocytic stem/progenitor cells
are the GN > CD transcripts (Table 2, Additional file 6,
Table S5, Figure 8), and include transcripts encoding
numerous potential therapeutic targets and/or cell-sur-
face expressed proteins. In addition to PROM1, CHI3L1
was also identified by the analysis. CHI13L1 (YKL-40) is
expressed in a small percentage of glioblastoma cells
upon initial diagnosis, but exhibits profound up regula-
tion upon tumor recurrence [27]. The regulator of G pro-
tein signaling 5, RGS5, is over expressed in highly
angiogenic astrocytomas and RGS5 expression is specifi-
cally up regulated in the vasculature of premalignant
lesions [35]. FKBP5 is over expressed in gliomas and
down regulation of FKBP5 expression using siRNAs sup-
presses glioma cell growth [36]. IGFBP2 over expression
has been demonstrated to promote glioma growth as well
as progression from low to high grade in mouse models
[37]. Over expression of transcripts encoding transmem-
brane proteins KCNMB4, a neural-specific β subunit of a
large-conductance, calcium-sensitive potassium channel
associated with glioma cell growth [38], and LPHN2, a
putative G-protein coupled receptor, were both identified
by the comparative microarray analysis. As were ASTN1,
an adhesion molecule associated with neuronal migration
Figure 7 Intersection of microarray data identifies markers of 
premalignant astrocytic stem-like/progenitor cells. Venn diagram 
depicting the overlap between the four pair wise comparisons: GvC, 
GvD, NvC and NvD that was used to identify the 311 transcripts exhib-
iting similar changes in expression patterns in trisomic BG01V APCs 
(samples G) and glioblastoma patients (samples N) relative to diploid 
H9 APCs (samples C) and CCF-STTG1 astrocytoma cells (samples D), 
which constitutes the GNvCD gene list shown in Additional file 6, Table 
S5.
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Table 2: Markers over expressed in premalignant astrocytic stem-like/progenitor cells (GN > CD).
Gene
symbol
Accession
Number
Fold change
RGS5 NM_003617 30.43
CHI3L1 NM_001276 25.26
FKBP5 NM_004117 10.71
LPHN2 NM_012302 10.33
SLC40A1 NM_014585 9.16
IGFBP2 NM_000597 8.42
SERPINB9 NM_004155 8.10
PPP2R2B NM_181674 7.59
PROM1 NM_006017 7.34
ST8SIA4 NM_005668 7.23
GPC4 NM_001448 7.11
P2RY5 NM_005767 6.18
LASS6 NM_203463 5.41
SNTB1 NM_021021 5.24
KCNMB4 NM_014505 5.18
ASTN1 NM_004319 4.77
CCDC3 NM_031455 4.76
RHOU NM_021205 4.74
MTUS1 NM_001001924 4.32
PPAP2B NM_003713 3.60
ZNF238 NM_205768 3.53
A subset of gene transcripts over expressed in trisomic BG01V APCs (G) and glioblastoma samples (N) relative to diploid H9 APCs (C) and CCF-
STTG1 astrocytoma cells (D). Fold change was derived from GNvCD group comparison in Additional file 6, Table S5, filtered at p value < 0.02.Gopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
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along astroglial fibers [39], and GPC4, a cell-surface
expressed proteoglycan that may play a role in controlling
cell division [40]. Additional over expressed transcripts
identified by comparative global microarray analysis
using  in vitro differentiated trisomic BG01V APCs
include those encoding signaling molecules such as the
protein phosphatase, PPP2R2B, the purinergic receptor,
P2RY5, the ras homolog, RHOU, and others not previ-
ously associated with astrocytomas or astrocytic cancer
stem cells.
Inherent genetic instability of cultured hESCs renders
them susceptible to gain or loss of entire chromosomes
and/or discrete chromosomal regions. Gain of chromo-
somes 12 or 17 has been reported in several other hESC
lines [2,3,7]. Amplification or deletion of discrete regions
of chromosome 20 and 5 as well as mosaic gain of chro-
mosome 12 has also been reported to arise spontaneously
in cultured hESC lines [6]. Significantly, neural stem cells
d e r i v e d  f r o m  s o m e  o f  t h e s e  h E S C  v a r i a n t s  h a v e  b e e n
clearly demonstrated to exhibit several features of neo-
plastic transformation in vivo. Thus, it is highly unlikely
that trisomic BG01V hESCs line are unique in their abil-
ity to differentiate into premalignant astrocytic stem/pro-
genitor cells upon in vitro directed differentiation. The in
vivo evidence of neoplastic transformation of differenti-
ated hESC variants suggests that the propensity toward
transformation may be a somewhat common occurrence
and underscores the absolute necessity of subjecting all
hESC-derived cells to functional characterization prior to
their use in therapeutic regimens [6]. Although BG01V
hESCs may not be unique in exhibiting features of prema-
lignant transformation following differentiation, the con-
spicuous differences in expression profiles of BG01V
APCs and H9 APCs, combined with the striking similari-
ties in expression profiles of BG01V APCs and glioblas-
toma samples suggest that gain of chromosomes X, 12
and/or 17 may be one of several routes by which transfor-
mation can be initiated in astrocytic progenitor cells.
However, we cannot rule out the possibility that genetic
events other than trisomy played a role in the initiation of
premalignant transformation observed here since the tri-
somic hESC line, BG01V, is not a derivative of the diploid
hESC line, H9.
That a constellation of gain-of-function and/or loss-of-
function mutations in multiple genes is required for
malignant transformation has been known for decades
[41,42]. Aneuploidy, however, has been associated with
cancer for more than a century [43]. Given the high-
degree of aneuploidy observed in glioblastoma patient
samples, it is difficult to distinguish those genes or chro-
mosomal regions associated with tumor initiation or
propagation from those representing random events aris-
ing from the inevitable genetic instability common to
these high-grade tumors. Comprehensive analysis of
chromosomal aberrations in 141 glioma samples identi-
fied approximately 35 broad and focal regions of gene
amplifications and deletions demonstrating statistically
significant associations in human gliomas [44], and
revealed that amplification of a number of chromosomal
regions, including chromosomes 12 and 17, met the
threshold for significance in these glioma samples,
including secondary glioblastomas arising from low-
grade gliomas. High-resolution copy number analysis of
glioma samples also revealed recurrent gain of multiple
sub-regions of chromosome 12 in secondary glioblasto-
mas arising from lower grade astrocytomas [45]. Since
recurrent gain of chromosomes 12 or 17 has been
observed in a number of karyotypically abnormal hESC
lines [2-4,7], this also suggests that other aneuploid hESC
variants might exhibit properties similar to trisomic
BG01V cells upon differentiation into astrocytes.
Dot plots for several additional markers associated with
gliomas are shown in Additional file 7, Figure S2. Ampli-
fication of EGFR (or gain of chromosome 7) is often seen
in high-grade gliomas [11]. Not surprisingly, over expres-
sion of EGFR  in some glioblastoma samples is also
observed here (Additional file 7, Figure S2, panel A). Loss
of chromosome 10 (or regions of chromosome 10 encod-
ing the PTEN locus) is associated with some de novo glio-
blastomas, and reduced PTEN  expression in some
glioblastoma samples is seen here (panel B). IL13RA2 is
reportedly over expressed in ~90% of glioblastoma sam-
ples. Exon microarray analysis indicates bifurcation of
patient samples into two distinct groups; one group
exhibits significant over expression of IL13RA2  tran-
scripts, whereas IL13RA2 is expressed at levels similar to
controls in the other group of patient samples (D). Rela-
tive expression levels of PDGFB (F), PDGFRA (G) PDG-
FRB (H) are also shown in Additional file 7, Figure S2.
Although median expression level of PDGFRB  is
decreased relative to controls, there is a wide range of
expression levels, which may also reflect distinct glioma
subtypes. Mutations in a number of genes have also been
associated with gliomagenesis, although many are
somatic mutations that do not necessarily result in
expression level changes [11]. Several are shown in Addi-
tional file 7, Figure S2, including AKT1 (C), NRG1 (E),
TP53 (I), MDM2 (J), NF1 (K) and RB1 (L). There is no
obvious correlation in relative expression levels of these
markers in glioblastoma samples and/or premalignant
astrocytic progenitors, with perhaps the exception of
NRG1 (HER2 ligand) where expression levels are lower in
all samples relative to the diploid H9 APCs. Although tri-
somy for chromosomes 12 and 17 may be one potential
precipitating event resulting in transformation of BG01V
hESCs into premalignant APCs during differentiation,
not all differences in relative gene expression levels can be
explained by the trisomy. Dot plots for a number of genesGopalakrishna-Pillai and Iverson BMC Medical Genomics 2010, 3:12
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that are known to be expressed in astrocytes, known to be
associated with cancer and known to map to chromo-
somes 12 or 17 are also shown in Additional file 7, Figure
S2, including STAT3 (panel M, chromosome 17) where
expression levels in glioblastoma, BG01V APCs and
CCF-STTG1 samples are higher than H9 APCs, ERBB2
(HER2 - panel N - chromosome 17) where expression lev-
els are higher in BG01V APCs and glioblastoma samples
Figure 8 Over expressed transcripts include known and novel markers of premalignant astrocytic stem/progenitor cells. Individual gene dot 
plots showing expression levels of several over expressed transcripts in all twenty-three glioblastoma patient samples (purple, N), three trisomic BG01V 
APCs samples (green, G), three CCF-STTG1 astrocytoma cell samples (blue, D) and diploid H9 APCs (red, C). Transcripts shown are PROM1 (panel A), 
CHI3L1 (panel B), RGS5 (panel C), IGFBP2 (panel D), PPP2R2B (panel E), LPHN2 (panel F), KCNMB4 (panel G), ASTN1 (panel H) and GPC4 (panel I).
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but also high in diploid H9 APCs, and both RARA (panel
O, chromosome 17) and RARG (panel P, chromosome
12), where expression levels are higher in BG01V APCs
relative to H9 APCs but also lower in glioblastoma sam-
ples. Thus, not all transcripts encoded by genes that map
to chromosomes X, 12 and/or 17 are over expressed in
BG01V APCs and not all over expressed gene transcripts
in BG01V APCs map to chromosomes X, 12 and/or 17.
We think that most gene transcripts that are over
expressed in BG01V APCs relative to H9 APCs are conse-
quences of premalignant transformation rather than
causes of premalignant transformation.
Nonetheless, gain of chromosomes X, 12 and/or 17 has
also been observed in carcinoma in situ of the testis,
which is thought to be the common pre-invasive progeni-
tor cell (or precancerous stem cell) that gives rise to both
seminoma and non-seminomatous testicular germ cell
tumors [46]. Recurrent amplification of 17q23.2 in some
breast tumors has recently been reduced to a 249 kb min-
imal region including potential tumor driver genes,
RPS6KB1 and mir-21 [47]. Finding gains of similar chro-
mosomal regions in tumors whose origins are unrelated
to the nervous system suggests that trisomy for these
chromosomal regions is a type of moderate aneuploidy
common to other precancerous progenitor or stem cells
and hypothesized to be an initiator of tumorigenesis [48-
50]. This suggests that directed differentiation of trisomic
hESC variants along other lineages might be used to sim-
ulate early molecular events occurring enroute to malig-
nant transformation of other cancers and to identify
diagnostic markers and/or molecular targets amenable to
therapeutic intervention.
Conclusions
An in vitro culture system was developed in which dip-
loid and trisomic hESCs were differentiated into homoge-
nous populations of human astrocytic progenitor cells
(APCs) suitable for global gene expression profiling using
high-density microarrays. Expression profiles of the
hESC-derived APCs were compared to a malignant astro-
cytoma cell line and glioblastoma tumor samples, and
used to demonstrate that trisomic APCs share many
properties with the astrocytoma cell line and glioblas-
toma samples. The bioinformatic analysis employed here
facilitated identification of numerous differentially
expressed transcripts that are characteristic of astrocytic
cancer cells. This analysis was also used to identify bio-
markers of the subpopulation of astrocytic cancer stem
cells that comprise only a small fraction of diverse cell
types found in heterogeneous brain tumors. Directed dif-
ferentiation of trisomic hESCs is a powerful in vitro
model system for investigating changes in gene expres-
sion occurring enroute to malignant transformation and
for identifying molecular markers characteristic of pre-
malignant stem/progenitor cells that may be amenable
for therapeutic intervention for patients with astrocy-
tomas. The results of this analysis further underscore the
need for exercising extreme caution when utilizing stem
cells in regenerative medicine.
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